P/B
0,9
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
$21.5M
Market Cap • 10/8/2026
2005
(21 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
Israel
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
10,1
EPS
—
Market Cap
Market Cap
21,5M
EV
5,5M
EV/Revenue
0
EV/EBITDA
-0,4
EV/EBIT
-0,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-36,4%
Total Yield
-36,4%
Payout
0%
Retained Earnings
-9,8M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
2,6%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
127,8%
CAGR Net Income 5Y
135,3%
CAGR OCF 5Y
92,8%
Leverage
N.D./EBITDA
1,3
Debt/Equity
0%
Current Ratio
36,4
Quick Ratio
35,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!